Please login to the form below

Not currently logged in
Email:
Password:

MSD to acquire Inspire Pharmaceuticals

MSD (Merck in the US and Canada) has entered into a deal worth $430m to acquire Inspire Pharmaceuticals, a speciality pharma company focused on ophthalmic products

MSD (known as Merck in the US and Canada) has entered into a deal to acquire Inspire Pharmaceuticals, a speciality pharma company focused the development and commercialisation of ophthalmic products.

The transaction, which has been approved by the boards of directors of both companies, has a total cash value of around $430m. Under the terms of the deal, MSD will commence a tender offer for all outstanding common stock of Inspire at a price of $5.00 per share in cash, a 26 per cent premium to the closing price of Inspire's common stock on April 4, 2011. 

"Merck[MSD] continues to build upon its long-term commitment to improving therapeutic options for the treatment of eye diseases," said Beverly Lybrand, senior vice president and general manager, neuroscience and ophthalmology, Merck. "This acquisition combines the talented commercialisation organisation at Inspire with the excellent team already in place at Merck thereby strengthening our ophthalmology business and positioning us for future growth with an expanded portfolio. This deal helps address the needs of patients and customers in ophthalmology and creates value for both companies."

The closing of the tender offer is subject to completion of certain conditions, including the tender of a number of Inspire shares that, together with shares owned by Merck, represent at least a majority of the total number of Inspire's outstanding shares (assuming the exercise of all options and vesting of restricted stock units), the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. Upon the completion of the tender offer, Merck will acquire all remaining shares through a second-step merger.

6th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...